| [1] |
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3):162–174.
|
| [2] |
Zhao W, Xu Y, Xu J, et al. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially[J]. Int Immunopharmacol, 2015, 26(2):314–321.
|
| [3] |
Keskinov AA, Shurin MR. Myeloid regulatory cells in tumor spreading and metastasis[J]. Immunobiology, 2015, 220(2):236–242.
|
| [4] |
Zhang H, Li ZL, Ye SB, et al. Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator[J]. Cancer Immunol Immunother, 2015.[Epub ahead of print]
|
| [5] |
Zhang B, Wang Z, Wu L, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patientswith colorectal carcinoma[J]. PLoS One, 2013, 8(2):e57114.
|
| [6] |
Huang H, Zhang G, Li G, et al. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC[J]. Tumour Biol, 2015, 36(10):7987–7996.
|
| [7] |
Tian T, Gu X, Zhang B, et al. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer[J]. Cancer Biomark, 2015, 15(4):425–432.
|
| [8] |
Wang Z, Zhang L, Wang H, et al. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients[J]. Cancer Immunol Immunother, 2015, 64(3):389–399.
|
| [9] |
Arihara F, Mizukoshi E, Kitahara M, et al. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis[J]. Cancer Immunol Immunother, 2013, 62(8):1421–1430.
|
| [10] |
Li G, Wu K, Tao K, et al. Vasoactive intestinal peptide induces CD14+HLA-DR-/low myeloid-derived suppressor cells in gastric cancer[J]. Mol Med Rep, 2015, 12(1):760–768.
|
| [11] |
Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells[J]. Nat Rev Cancer, 2013, 13(10):739–752.
|
| [12] |
Chen MF, Kuan FC, Yen TC, et al. IL-6-stimulated CD11b+ CD14+ HLA-DR-myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus[J]. Oncotarget, 2014, 5(18):8716–8728.
|
| [13] |
Oh K, Lee OY, Shon SY, et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model[J]. Breast Cancer Res, 2013, 15(5):R79.
|
| [14] |
Ma S, Cheng Q, Cai Y, et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma[J]. Cancer Res, 2014, 74(7):1969–1982.
|
| [15] |
Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J]. Sci Transl Med, 2014, 6(237):237ra67.
|
| [16] |
Balwit JM, Hwu P, Urba WJ, et al. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program[J]. J Transl Med, 2011, 9:18.
|
| [17] |
Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1[J]. J Immunol, 2009, 182(1):240–249.
|
| [18] |
Sumida K, Wakita D, Narita Y, et al. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses[J]. Eur J Immunol, 2012, 42(8):2060–2072.
|
| [19] |
Ding Y, Shen J, Zhang G, et al. CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer[J]. Oncotarget, 2015, 6(36):38901–38911.
|
| [20] |
Stenvold H, Donnem T, Andersen S, et al. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome[J]. Lung Cancer, 2012, 75(2):235–241.
|
| [21] |
Liu Y, Lai L, Chen Q, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN[J]. J Immunol, 2012, 188(11):5500–5510.
|
| [22] |
Corzo CA, Condamine T, Lu L, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment[J]. J Exp Med, 2010, 207(11):2439–2453.
|
| [23] |
Guedez L, Jensen-Taubman S, Bourboulia D, et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis[J]. J Immunother, 2012, 35(6):502–512.
|
| [24] |
Forrester E, Chytil A, Bierie B, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis[J]. Cancer Res, 2005, 65(6):2296–2302.
|
| [25] |
De Sanctis F, Solito S, Ugel S, et al. MDSC in cancer: Conceiving new prognostic and therapeutic targets[J]. Biochim Biophys Acta, 2015. [Epub ahead of print]
|
| [26] |
Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas[J]. Clin Cancer Res, 1999, 5(5):1107–1113.
|
| [27] |
Marçola M, Rodrigues CE. Endothelial progenitor cells in tumor angiogenesis: another brick in the wall[J]. Stem Cells Int, 2015, 2015:832649
|
| [28] |
Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer[J]. Cancer Res, 2006, 66(14):7341–7347.
|
| [29] |
Mulligan JK, Rosenzweig SA, Young MR. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2[J]. J Immunother, 2010, 33(2):126–135.
|
| [30] |
Madlambayan GJ, Butler JM, Hosaka K, et al. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger[J]. Blood, 2009, 114(19):4310–4319.
|
| [31] |
Li B, Vincent A, Cates J, et al. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site[J]. Cancer Res, 2009, 69(1):338–348.
|
| [32] |
Huang S, Tang Y, Cai X, et al. Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells[J]. Biochem Biophys Res Commun, 2012, 423(3):467–472.
|
| [33] |
Solito S, Marigo I, Pinton L, et al. Myeloid-derived suppressor cell heterogeneity in human cancers[J]. Ann N Y Acad Sci, 2014, 1319:47–65.
|
| [34] |
Srivastava MK, Sinha P, Clements VK, et al. Myeloid derive suppressor cells inhibitT cell activation by depleting cystine and cysteine[J]. Cancer Res, 2010, 70(1):68–77.
|
| [35] |
Draghiciu O, Lubbers J, Nijman HW, et al. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy[J]. Oncoimmunology, 2015, 4(1):e954829.
|
| [36] |
Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumournetwork: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells[J]. Immunology, 2013, 138(2):105–115.
|
| [37] |
Waldron TJ, Quatromoni JG, Karakasheva TA, et al. Myeloid derived suppressor cells: Targets for therapy[J]. Oncoimmunology, 2013, 2(4):e24117.
|
| [38] |
Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer[J]. Front Oncol, 2013, 3:49.
|
| [39] |
Ugel S, Peranzoni E, Desantis G, et al. Immune tolerance to tumor antigens occurs in a specialized environment of thespleen[J]. Cell Rep, 2012, 2(3):628–639
|
| [40] |
Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation ofmyeloid cells and immune response in cancer patients[J]. Cancer Res, 2006, 66(18):9299–9307.
|
| [41] |
Veltman JD, Lambers ME, van Nimwegen M, et al. Zoledronic acid impairs myeloid differentiationto tumour-associated macrophages in mesothelioma[J]. Br J Cancer, 2010, 103(5):629–641.
|
| [42] |
Roth F, De La Fuente AC, Vella JL, et al. Aptamer-mediated blockadeof IL4Rα triggers apoptosis of MDSC and limitstumor progression[J]. Cancer Res, 2012, 72(6):1373–1383.
|
| [43] |
Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity[J]. Cancer Cell Int, 2015, 15:106.
|
| [44] |
Mao Y, Sarhan D, Steven A, et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity[J]. Clin Cancer Res, 2014, 20(15):4096–4106.
|
| [45] |
Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention by cyclooxygenase-2inhibition reduces immature myeloid suppressorcell expansion[J]. Int Immunopharmacol, 2007, 7(2):140–151.
|
| [46] |
Veltman JD, Lambers ME, van Nimwegen M, et al. COX-2 inhibition improvesimmunotherapy and is associated withdecreased numbers of myeloid-derived suppressor cellsin mesothelioma. Celecoxib influences MDSC function[J]. BMC Cancer, 2010, 10:464.
|
| [47] |
Nefedova Y, Fishman M, Sherman S, et al. Mechanism of all-trans retinoic acideffect on tumor-associated myeloid-derived suppressorcells[J]. Cancer Res, 2007, 67(22):11021–11028.
|
| [48] |
Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination[J]. Cancer Res, 2003, 63(15):4441–4449.
|
| [49] |
Lathers DM, Clark JI, Achille NJ, et al. Phase IB study to improve immuneresponses in head and neck cancer patients using escalating doses of 25hydroxyvitamin D3[J]. Cancer Immuno limmunother, 2004, 53(5):422–430.
|